Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Positive Data and Regulatory Update from Planned Interim Analysis of Ph 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer Announced

February 1, 2023

KEYTRUDA® + Chemotherapy Significantly Improved OS Versus Chemotherapy in 1L Biliary Tract Cancer in KEYNOTE-966 Trial

February 1, 2023

ASCO GI: Ph 3 NAPOLI 3 trial of Onivyde® regimen demonstrating positive survival results in 1L metastatic pancreatic ductal adenocarcinoma presented

February 1, 2023

ASCO GI: Final Results and New Xerna™ TME Panel Biomarker Data from Ph 2 Trial of Bavituximab + Pembrolizumab in 1L HCC Patients announced

February 1, 2023

ASCO GI: Ph 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) Presented

February 1, 2023

Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer

January 17, 2023

Promising Top-Line Results from Ph 2 Trial of BXCL701 in small cell neuroendocrine metastatic castration-resistant prostate cancer (SCNC) patients announced

January 17, 2023

Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrated Meaningful Responses with Tovorafenib (DAY101) in Pediatric Low-Grade Glioma

January 17, 2023

Upcoming 2023 Readouts from Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib announced

January 17, 2023

Results from Ph 1 dose-expansion study of STRO-002 (luvelta) in patients with advanced ovarian cancer announced

January 17, 2023

Positive Top-line Results from Pivotal Ph 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate Cancer Announced

January 11, 2023

Pivotal LUNAR Study of TTFields + SoC in NSCLC Met Primary Overall Survival Endpoint

January 11, 2023

Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate Announced

January 11, 2023

Initial update on Ph 2 PRESERVE 3 trial of 1L platinum-based chemo and maintenance avelumab +/- trilaciclib  in patients with 1L locally advanced or metastatic urothelial carcinoma announced

January 11, 2023

Interim Data from Ph 1b/2 Study of Abequolixron (RGX-104) in R/R Lung Cancer Announced

January 11, 2023

Positive Clinical Data Update for Zotatifin Provided

January 11, 2023

Positive Top-Line Results from IMerge Ph 3 Trial of Imetelstat in Lower Risk MDS Announced

January 11, 2023

Results from INTRIGUE Ph 3 Clinical Study Demonstrate Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 Only

January 11, 2023

mOS of 21 Months in Advanced, Refractory Cancer Patients observed in Ph 2 trial of PDS0101-based triple combination therapy in advanced HPV-positive cancers

January 4, 2023

Positive Topline Data in Ph 2 Pivotal HERIZON-BTC-01 Trial of Zanidatamab announced

January 4, 2023

Complete Response Of The First Patient Treated In B-Cell Non-Hodgkin Lymphoma (B-NHL) Ph 1 Clinical Trial Of PMB-CT01 (BAFFR-CAR T Cells) announced

January 4, 2023

Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel + PD-1i and Carboplatin in Neoadjuvant Breast Cancer reported

January 4, 2023

FAILED TRIAL: PEARL Ph 3 trial for Imfinzi (durvalumab) monotherapy did not achieve statistical significance of improving OS vs chemo as a monotherapy treatment in PD-L1+ve mNSCLC patients

January 4, 2023

mRNA-4157/V940 + KEYTRUDA® (pembrolizumab) Met Primary Efficacy Endpoint in Ph 2b KEYNOTE-942 Trial

December 19, 2022

Zolbetuximab Meets Primary Endpoint in Ph 3 GLOW Trial as 1L Treatment in Claudin 18.2 +ve HER2-neg Locally Advanced Unresectable or Metastatic GEJ Cancers

December 19, 2022
Page1 … Page24 Page25 Page26 Page27 Page28 … Page30

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.